Tradestie Institutional Equity Comparison Engine
LH vs AMS โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LH Overall Edge
LH Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Labcorp Holdings Inc. (LH) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LH trades at 19.0x Forward P/E with 11.2% operating margin (+6.9% YoY revenue) versus AMS at 44.6x Forward P/E and -7.4% operating margin (+19.2% YoY). In options structure, LH sits in CONSOLIDATION (16th %ile IV; Dealer Gamma Walls on Pro) against AMS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
LH
LH 19.0x vs AMS 44.6x Fwd P/E
Growth & Margin Winner
LH
Op Margin 11.2% vs -7.4% ยท YoY +6.9% vs +19.2%
Momentum & Technical Winner
LH
1Y +39.0% vs -52.2% ยท 52W Pos 98% vs 6%
Options & Structure Winner
LH
CONSOLIDATION (16th %ile IV) vs UNCLASSIFIED (N/A IV)
LH
NYSE
Labcorp Holdings Inc.
Services-Medical Laboratories
$372.46
+0.53% 1D
Market Cap
$30.1B
1M Return
+17.14%
1Y Return
+39.05%
Forward P/E
19.0x
Unified AI Score
40.8 / 100
SELL
Tech 17.0
Fund 35.0
Flow 58.0
Mom 31.1
AMS
NYSE American
American Shared Hospital Services
Services-Medical Laboratories
$1.07
-0.93% 1D
Market Cap
$7.2M
1M Return
-16.41%
1Y Return
-52.23%
Forward P/E
44.6x
Unified AI Score
33.8 / 100
SELL
Tech 24.0
Fund 38.0
Flow 50.0
Mom 30.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
LH +39.05%
AMS -52.23%
Spread: +91.28 pp (LH Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | LH Revenue | AMS Revenue | LH Op. Margin | AMS Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $11.3B | $20M | 11.7% | 9.4% | LH |
| FY2019 | $11.6B | $20M | 11.5% | 7.5% | LH |
| FY2020 | $14.0B | $20M | 17.5% | -53.1% | LH |
| FY2021 | $13.1B | $20M | 23.2% | 7.7% | LH |
| FY2022 | $11.9B | $20M | 12.1% | 12.3% | AMS |
| FY2023 | $12.2B | $20M | 6.0% | 1.3% | LH |
| FY2024 | $13.0B | $30M | 8.4% | -9.9% | LH |
| FY2025 | $13.9B | $30M | 9.9% | -12.8% | LH |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | LH | AMS | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $30.1B | $7.2M | Larger Scale | LH |
| Trailing P/E Ratio Valuation | 30.4x | 44.6x | Lower Multiple | LH |
| Forward P/E Ratio Valuation | 19.0x | 44.6x | Lower Multiple | LH |
| Revenue Growth (YoY) Growth | +6.9% | +19.2% | Higher Growth | AMS |
| Operating Margin (TTM) Profitability | 11.2% | -7.4% | Higher Margin | LH |
| Net Profit Margin Profitability | 6.9% | -5.8% | Higher Margin | LH |
| Return on Equity (ROE) Capital Efficiency | 11.4% | -12.1% | Higher ROE | LH |
| 52-Week Range Position Momentum | 98% ($245โ$375) | 6% ($1โ$2) | Stronger Trend | LH |
| Beta / 30D Volatility Risk Regime | 0.37ฮฒ ยท 36% Vol | 0.18ฮฒ ยท 46% Vol | Lower Realized Risk | LH |
| Unified Institutional Score Composite Signal | 40.8 / 100 (SELL) | 33.8 / 100 (SELL) | Higher Composite | LH |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full LH vs AMS Buy Guide
LH
CONSOLIDATION
59d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
16th %ile
IV Regime
Compressed (<25th %ile)
AMS
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither LH nor AMS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.